相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Sunitinib in combination with docetaxel and prednisone in patients with metastatic hormone-refractory prostate cancer (mHRPC) - preliminary results
D. J. George et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients
Brett E. Houk et al.
CLINICAL CANCER RESEARCH (2009)
Altered nonrenal drug clearance in ESRD
Thomas D. Nolin
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2008)
Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck
Christophe Le Tourneau et al.
CURRENT OPINION IN ONCOLOGY (2008)
Sunitinib monotherapy in patients with advanced hepatocellular carcinoma (HCC): Insights from a multidisciplinary phase II study
A. X. Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer
Mark A. Socinski et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Systemic diseases with renal manifestations
Asha Rajashekar et al.
PRIMARY CARE (2008)
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management - The renal insufficiency and anticancer medications (IRMA) study
Vincent Launay-Vacher et al.
CANCER (2007)
A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities
J. G. Christensen
ANNALS OF ONCOLOGY (2007)
An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases
Dong Wook Kim et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Chronic kidney disease after nephrectorny in patients with renal cortical turnours: a retrospective cohort study
William C. Huang et al.
LANCET ONCOLOGY (2006)
Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects
Carlo L. Bello et al.
ANTI-CANCER DRUGS (2006)
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
S Faivre et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
AM O'Farrell et al.
BLOOD (2003)
SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model
LJ Murray et al.
CLINICAL & EXPERIMENTAL METASTASIS (2003)
分享论文
